| abstract |
Quinoxaline derivates have the formula (I), in which R<1> is C1-12-alkyl substituted by R<2>, C2-12-alkenyl substituted by R<2>, C2-12-alkinyl substituted by R<2>, C3-7-cycloalkyl substituted by R<2>, -(CH2)n-C6-12-aryl substituted by R<2> in the aryl or alkyl residue or -(CH2)n-hetaryl substituted by R<2> in the hetaryl or alkyl residue; R<4> is hydrogen, C1-12-alkyl substituted by R<2>, C2-12-alkenyl substituted by R<2>, C2-12-alkinyl substituted by R<2>, (CH2)n-C6-12-aryl substituted by R<2> in the aryl or alkyl residue, or -(CH2)n-hetaryl substituted by R<2> in the hetaryl or alkyl residue; R<5>, R<6>, R<7> and R<8> are the same or different and represent hydrogen, halogen, nitro, NR<9>R<10>, NHCOR<11>, SO2R<12>, C3-7-cycloalkyloxy, COR<13>, cyano, CF3, C1-6-alkyl, C1-4-alkoxy or imidazole possibly substituted by cyano, C1-4-alkyl or -COO-C1-6-alkyl or R<5> and R<6> or R<7> and R<8> represent a condensated benzene ring, and R<2> stands for -CO-R<3>, or -PO-XY and is present once or twice in the same or a different form. Also disclosed are the preparation of these derivates and their use in medicaments. |